반응식
[CH2:1]([O:3][C:4](=[O:25])[C:5]([NH:10][C:11]([C:13]1[CH:18]=[CH:17][C:16](Br)=[C:15]([O:20][CH2:21][CH:22]2[CH2:24][CH2:23]2)[N:14]=1)=[O:12])([CH2:8][CH3:9])[CH2:6][CH3:7])[CH3:2].Cl.[F:27][C:28]1([F:32])[CH2:31][NH:30][CH2:29]1>>[CH2:1]([O:3][C:4](=[O:25])[C:5]([NH:10][C:11]([C:13]1[CH:18]=[CH:17][C:16]([N:30]2[CH2:31][C:28]([F:32])([F:27])[CH2:29]2)=[C:15]([O:20][CH2:21][CH:22]2[CH2:24][CH2:23]2)[N:14]=1)=[O:12])([CH2:8][CH3:9])[CH2:6][CH3:7])[CH3:2]참가 물질
3
실험 절차
The title compound was synthesized in analogy to the procedure described in Example 69 a, using ethyl 2-(5-bromo-6-(cyclopropylmethoxy)picolinamido)-2-ethylbutanoate (Example 265) and 3,3-difluoroazetidine hydrochloride (CAN 288315-03-7) as starting materials. MS (EI): m/e=426.0 [M+H]+.
출처 및 근거
- ORD 기록
- ord-467a22096d2f4eb98c72d6897f9c1892
- 출처 데이터셋
- uspto-grants-2016_03
- 특허 번호
- US09290451B2
연결된 노트
불러오는 중…